Rodger L. Bıck

Q: What Schools Are Affiliated With Rodger L. Bıck

Rodger L. Bıck is affiliated with the following schools: University of California, Los Angeles, Wayne State University, Trakya University, University of Texas Southwestern Medical Center

Rodger L. Bıck's AcademicInfluence.com Rankings

Rodger L. Bıck

Medical

#2601

World Rank

#3032

Historical Rank

Hematology

#36

World Rank

#42

Historical Rank

medical Degrees

Rodger L. Bıck

Philosophy

#7480

World Rank

#10701

Historical Rank

Logic

#4524

World Rank

#5833

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Rodger L. Bıck's Degrees

Doctorate Medicine Harvard University
PhD Biochemistry Stanford University

Why Is Rodger L. Bıck Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rodger L. Bıck's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Coagulation abnormalities in malignancy: a review. (1992) (225)
Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. (1985) (216)
Cancer-associated thrombosis. (2003) (200)
Disseminated intravascular coagulation and related syndromes: a clinical review. (1988) (161)
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. (2008) (144)
An update on heparins at the beginning of the new millennium. (2000) (133)
Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. (1998) (129)
Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. (1998) (127)
Clinical relevance of antithrombin III. (1982) (126)
Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. (1996) (110)
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent (2002) (105)
Recurrent Miscarriage Syndrome and Infertility Due to Blood Coagulation Protein/Platelet Defects: A Review and Update (2005) (92)
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. (1998) (91)
New Anticoagulants for the Cardiovascular Patient (1995) (91)
Disseminated Intravascular Coagulation: A Review of Etiology, Pathophysiology, Diagnosis, and Management: Guidelines for Care (2002) (89)
Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. (2003) (89)
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. (2008) (83)
Antiphospholipid syndrome and thrombosis. (1999) (82)
Sticky Platelet Syndrome: A Common Cause of Unexplained Arterial and Venous Thrombosis (1998) (79)
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. (2005) (79)
Recurrent Miscarriage Syndrome due to Blood Coagulation Protein/Platelet Defects: Prevalence, Treatment and Outcome Results (2000) (75)
Survival of heparins, oral anticoagulants, and aspirin after the year 2010. (2008) (74)
Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. (1977) (73)
The antiphospholipid and thrombosis syndromes. (1994) (72)
Antiphospholipid-thrombosis syndromes. (2003) (70)
Thrombosis and hemorrhage in oncology patients. (1996) (70)
Antiphospholipid-Thrombosis Syndromes (1999) (70)
Disseminated intravascular coagulation. Objective criteria for diagnosis and management. (1994) (67)
Hematology : clinical and laboratory practice (1993) (67)
Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). (1992) (67)
Generic low-molecular-weight heparins: some practical considerations. (2004) (66)
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. (1998) (66)
A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation. (1976) (60)
Syndromes of hypercoagulability and thrombosis: a review. (1994) (60)
Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. (1992) (59)
Disseminated intravascular coagulation. (1977) (57)
Antiphospholipid and thrombosis syndromes. (1994) (57)
Alterations of hemostasis associated with cardiopulmonary bypass. (1976) (57)
Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications (2006) (55)
Hypercoagulability and thrombosis. (1992) (54)
Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. (2003) (53)
Antithrombin III patterns in disseminated intravascular coagulation. (1980) (53)
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. (2003) (53)
Treatment of hereditary and acquired thrombophilic disorders. (1999) (49)
Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. (1983) (48)
Disseminated Intravascular Coagulation (1999) (45)
The clinical significance of fibrinogen degradation products. (1982) (45)
Syndromes of disseminated intravascular coagulation in obstetrics, pregnancy, and gynecology. Objective criteria for diagnosis and management. (2000) (45)
Disseminated intravascular coagulation and related syndromes: Etiology, pathophysiology, diagnosis, and management (1978) (45)
The clinical spectrum of antiphospholipid syndrome. (2008) (44)
Platelet function defects: a clinical review. (1992) (43)
Hypercoagulability and thrombosis. (1994) (40)
Physiology of hemostasis. (1994) (40)
Disorders of Hemostasis and Thrombosis (1985) (39)
International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. (1998) (39)
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. (1982) (39)
Clinical Aspects of Heparin-Induced Thrombocytopenia and Thrombosis and other Side Effects of Heparin Therapy (1999) (38)
Anticardiolipin antibodies and thrombosis. (1992) (37)
Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States (1999) (35)
Molecular Markers of Hemostatic Activation: Applications in the Diagnosis of Thrombosis and Vascular and Thrombotic Disorders (1995) (35)
Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. (2000) (35)
Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice (1992) (33)
Long-Term Outpatient Dalteparin (Fragmin) Therapy for Arterial and Venous Thrombosis: Efficacy and Safety—A Preliminary Report (1999) (33)
The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. (1993) (32)
Bleeding times, platelet adhesion, and aspirin. (1977) (32)
Evaluation of a New Hydroxyethyl Starch, Preparation (Hextend™) on Selected Coagulation Parameters (1995) (31)
DISSEMINATED INTRAVASCULAR COAGULATION: A CLINICAL/LABORATORY STUDY OF 48 PATIENTS (1981) (31)
Hereditary and Acquired Thrombophilic Disorders (2006) (30)
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. (1998) (30)
The Antiphospholipid Thrombosis Syndromes: A Common Multidisciplinary Medical Problem (1997) (29)
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. (2004) (29)
Fibrinolytic activity in acute myocardial infarction. (1972) (29)
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. (1983) (28)
Clinical use of intrapulmonary heparin. (1985) (27)
Antiphospholipid antibodies in coronary artery disease: a review. (1994) (27)
State-of-the-Art Review: Antiphospholipid Thrombosis Syndromes (2001) (26)
Coagulation abnormalities in patients with precocious coronary artery thrombosis and patients failing coronary artery bypass grafting and percutaneous transcoronary angioplasty. (1993) (26)
Antithrombin Agents: The New Class of Anticoagulant and Antithrombotic Drugs (1999) (25)
Hemostatic Defects Induced by Cardiopulmonary Bypass (1975) (25)
Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. (1997) (25)
Acquired defects of fibrinolysis associated with thrombosis. (1999) (25)
Deep vein thrombosis. Diagnosis and management. (1994) (24)
Hereditary Hemorrhagic Telangiectasia And Disseminated Intravascular Coagulation: A New Clinical Syndrome (1981) (23)
Disseminated intravascular coagulation. Objective laboratory diagnostic criteria and guidelines for management. (1994) (23)
Cancer-associated thrombosis: focus on extended therapy with dalteparin. (2006) (23)
Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. (2003) (22)
Management of Thrombotic and Cardiovascular Disorders in the New Millenium (2003) (22)
Syndromes of Thrombosis and Hypercoagulability: Congenital and Acquired Thrombophilias (1998) (22)
Fetal Wastage Syndrome due to Blood Protein/Platelet Defects: Results of Prevalence Studies and Treatment Outcome with Low-Dose Heparin and Low-Dose Aspirin (1995) (22)
Recurrent miscarriage: causes, evaluation, and treatment. (1998) (21)
Hematological complications in obstetrics, pregnancy, and gynecology (2006) (19)
State-of-the-Art Review : Disseminated Intravascular Coagulation: Objective Criteria for Clinical and Laboratory Diagnosis and Assessment of Therapeutic Response (1995) (19)
Laboratory diagnosis of antiphospholipid syndromes. (1995) (18)
Current trends in the development of anticoagulant and antithrombotic drugs. (1994) (18)
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. (1984) (18)
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. (1995) (18)
Disseminated Intravascular Coagulation and Blood Component Therapy (2003) (18)
The Available Low Molecular Weight Heparin Preparations Are Not the Same (1997) (18)
Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy (2006) (18)
The antiphospholipid and thrombosis (APL-T) syndromes. Clinical and laboratory correlates. (1995) (17)
Adriamycin and fibrinolysis. (1976) (17)
IN-VIVO PLATELET INHIBITION BY PIRACETAM (1979) (17)
Thrombotic thrombocytopenic purpura. An extended editorial. (2008) (17)
Role of antithrombin III in clinical management of pulmonary embolization. (1984) (17)
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. (2003) (16)
Therapy for Venous Thrombosis: Guidelines for a Competent and Cost-effective Approach (1999) (16)
Antiphospholipid syndrome in pregnancy. (2008) (16)
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management. (2008) (16)
Blood protein defects associated with thrombosis. Laboratory assessment. (1995) (16)
Development of generic low molecular weight heparins: a perspective. (2005) (15)
Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism (2000) (15)
A Clinical Comparison Of Chromogenic, Fluorometric, And Natural (Fibrinogen) Substrate Assays For Determination Of Antithrombin-III (1981) (14)
Acquired platelet function defects. (1992) (14)
Hyperfibrinolysis in cirrhosis. (1973) (14)
Hereditary and acquired thrombophilia. Part I. Preface. (1999) (14)
Laboratory evaluation of the antiphospholipid syndrome. (2008) (14)
Current Status of Thrombosis: A Multidisciplinary Medical Issue and Major American Health Problem—Beyond the Year 2000 (1997) (14)
Laboratory evaluation of platelet dysfunction. (1995) (13)
Vascular disorders associated with thrombohemorrhagic phenomena. (2008) (13)
Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? (2008) (13)
State-of-the-Art Review: Vascular Thrombohemorrhagic Disorders: Hereditary and Acquired (2001) (13)
Clinical hemostasis practice: the major impact of laboratory automation. (1983) (13)
Drug-induced alterations of hemostasis and fibrinolysis. (1992) (12)
Platelet function defects associated with hemorrhage or thrombosis. (1994) (12)
State-of-the-Art-Review : Thrombogenesis in Myocardial Infarction and Related Syndromes: The Role of Molecular Markers in Diagnosis and Management (1999) (12)
Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. (1999) (12)
Disseminated intravascular coagulation syndromes. (1992) (12)
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. (1999) (12)
Stasis Ulcers Refractory to Therapy—Accelerated Healing by Treatment With Clopidogrel ± Dalteparin: A Preliminary Report (2001) (12)
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. (2007) (12)
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. (2002) (10)
Anemia of malignancy. (1996) (10)
Treatment options for patients who have antiphospholipid syndromes. (2008) (10)
Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. (1983) (10)
Issues of thrombosis and hemorrhagic events in patients with cancer. (1998) (10)
Differentiation of Low-Molecular-Weight Heparins: Practical Implications (2004) (10)
Prothrombin complex concentrate: Use in controlling the hemorrhagic diathesis of chronic liver disease (1975) (9)
Contaminant in the Recalled Unfractionated Heparin Preparations: Where is the Problem? (2008) (9)
Antithrombin III and factor VIII in patients with neoplasms. (1978) (9)
Introduction to thrombosis proficient and cost-effective approaches to thrombosis. (2003) (9)
Daunomycin and fibrinolysis. (1976) (9)
Thrombophilic Causes of Retinal Vascular Thrombosis: Etiology and Treatment Outcomes (2002) (9)
The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products (2008) (9)
Laboratory modalities for assessing hemostasis during cardiopulmonary bypass. (2008) (9)
Clinical implications of molecular markers in hemostasis and thrombosis. (1984) (9)
Vascular thrombohemorrhagic disorders: hereditary and acquired. (2001) (9)
Surgical hemostasis with a factor XL-containing concentrate. (1974) (8)
Vascular Damage Correlates between Heparin-Induced Thrombocytopenia and the Antiphospholipid Syndrome (1999) (8)
Antithrombin-III as a Diagnostic AID in Disseminated Intravascular Coagulation (1977) (8)
Generic Low Molecular Weight Heparins: A Significant Dilemma (2005) (8)
Qualitative Platelet Defects (1992) (7)
L-Asparaginase-Provoked Seizures as Singular Expression of Central Nervous Toxicity (2000) (7)
Free‐Standing Cancer Centers: Rationale for Improving Cancer Care Delivery (1989) (6)
Anemia of malignancy. (1995) (6)
Disseminated Intravascular Coagulopathy (DIC): Pathophysiology, Laboratory Diagnosis, and Management (2000) (6)
Malaria transmission among narcotic addicts. A report of ten cases and review of the literature. (1971) (5)
Cardiopulmonary Bypass Hemorrhage: Aggravation by Pre-Op Ingestion of Antiplatelet Agents (1979) (5)
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. (1999) (5)
Low molecular weight heparins in the outpatient management of venous thromboembolism. (1999) (5)
Reduced Immunogenic Potential of Membrane Filtered Bovine Thrombin Preparations for Hemostatic Application (2009) (5)
Are the Current Guidelines for the Acceptance of Generic Low Molecular Weight Heparins Adequate? (2003) (5)
Why a New Journal on Thrombosis and Hemostasis? (1995) (5)
Disorders of Hemostasis and Thrombosis: Principles of Clinical Practice (1985) (5)
Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology (2003) (5)
Anticoagulant And Antiplatelet Therapy (2019) (4)
Thrombosis and thrombophilia: diagnosis and management. (2003) (4)
Current Developments in Anticoagulant and Antithrombotic Agents (1999) (4)
Contaminants in heparins continue to be unfolded. (2008) (4)
Comparison of Immunogenic Potentials of Bovine Thrombin Preparations (2009) (4)
Antiphospholipid thrombosis syndromes. (2001) (4)
Piracetam: A New Platelet Suppressing Drug (1981) (4)
Fibrinolytic Activity: Changes Induced With Oral Contraceptives (1972) (4)
Iron Deficiency Anemia (1990) (4)
Disorders of thrombosis and hemostasis (2012) (4)
Increased levels of inflammatory mediators in lung cancer and their modulation by oral anticoagulant treatment. (2006) (3)
A comparative study of the DuPont antithrombin III and fibrinogen assay systems. (1985) (3)
Hemostasis Abnormalities Associated With Prosthetic Devices and Organ Transplantation (1992) (3)
The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors: Experimental and Clinical Observations (2008) (3)
Factor V: a Simplified One-Stage Assay using a Stabilized Artificial Substrate (1973) (3)
Potential Thrombogenic Complications With the Use of Recombinant Activated Factor VII in Combat Trauma (2007) (3)
Understanding the Antiphospholipid-Thrombosis Syndromes (1995) (3)
PATHOGENESIS OF ATRIAL FIBRILLATION‐POTENTIAL ROLE OF INFLAMMATORY RESPONSE. (2006) (3)
Antithrombotic therapy: current practice and future trends. (2005) (3)
Sticky Platelet Syndrome: The Clinical Spectrum of Thrombosis. (2005) (3)
Discrepant AT-III and fibrinogen levels on the DuPont acaTM system. (1983) (3)
Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin. (2006) (3)
Prothrombin Complex Concentrates and Chronic Liver Disease (1975) (2)
Antigenic (Immunogenic) Profiling of Bovine Thrombin and its Purified Forms (2008) (2)
Thrombohemorrhagic Defects and Recurrent Miscarriage Syndrome. (2004) (2)
Antithrombins And Coronary Artery Disease (1984) (2)
Current perspectives in antithrombotic therapy (2001) (2)
Oral Anticoagulants in Thromboembolic Disease (1995) (2)
Thromboprophylaxis in surgical patients. (2004) (2)
Acute Leukemias: FAB Classification and Clinical Correlates (1994) (2)
Management of venous thrombosis and thromboembolism: prevention and treatment. (2002) (2)
Studies Related To Tobacco Glycoprotein: A Claimed Activator Of Coagulation, Fibrinolysis, Complement, Kinin, And A Claimed Allergen (1981) (2)
Dr. Eberhard F. Mammen Remembered: A Great Clinician-Scientist, Mentor, and Friend (2008) (2)
Paroxysmal Nocturnal Hemoglobinuria (1994) (1)
Book Review (2008) (1)
Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Receptors. Experimental and Clinical Observations. (2006) (1)
Differential Activation of Prothrombin by Factor Xa, Ecarin and Taipan Venom as Studied by ProteinChip Array Profiling with Surface Enhanced Laser Desorption Ionization (SELDI) Analysis (2007) (1)
Thrombolytic Therapy and Its Uses (1995) (1)
Alterations Of Hemostasis Associated With Malignancy (2019) (1)
Evidence for a new activation phase clotting abnormality in a patient with the Hughes-Stoven syndrome. (1974) (1)
Monitoring Heparin Therapy To Manage Thrombotic Disease (1995) (1)
Histiocytic medullary reticulosis in two Chinese women. (1974) (1)
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung. (1976) (1)
Ticlopidine and Clopidogrel: Do They Have Direct Vascular Effects? (1997) (1)
Disseminated Intravascular Coagulation: A Clinical/Laboratory Correlation In 48 Patients (1981) (1)
Basic Concepts Of Hemostasis (2021) (1)
Fibrinolytic potential in polycythemia rubra vera. (1974) (1)
Antiphospholipid syndromes. (2008) (1)
Fatal purpura fulminans following total cardiopulmonary bypass. (1973) (1)
Dengue Fever and Thrombocytopenia: A Deadly Duo. (2006) (1)
The Effect Of Piracetam In Preventing Recurrent Deep Venous Thrombosis (1981) (1)
Book Reviews (1995) (0)
The Large Scale Preparation of Clottable Fibrinogen-Free, High Purity, High Potency Factor VIII Concentrate (1977) (0)
Variation in the thrombin activatable fibrinolytic inhibitor (TAFI) modulation by heparin: Therapeutic implications. (2003) (0)
Disseminated Intravascular Coagulation (Dic) And Related Syndromes (2019) (0)
Relative Immunologic Potential of Bovine Prothrombin and Purified Thrombins (2008) (0)
Hematological Complications in Obstetrics, Pregnancy, and Gynecology: Plate section (2006) (0)
Differential Prevalence of Anti‐Heparin PF4 Immunoglobulin Subtypes in Patients Treated with Reviparin, Enoxaparin, and Certoparin. Implications in HIT Pathogenesis. (2008) (0)
Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia. (2005) (0)
Up-regulation of inflammatory and thrombotic mediators in lung cancer and their modulation by oral anticoagulantion (2007) (0)
Argatroban and Lepirudin: Clinical Trials to Clinical Practice (2005) (0)
Trypsin Mediates the Activation of Thrombin Activatable Fibrinolytic Inhibitor: Potential Clinical Implications (2007) (0)
Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology. (2004) (0)
Hematological Complications in Obstetrics, Pregnancy, and Gynecology: Thromboprophylaxis and treatment of thrombosis in pregnancy (2006) (0)
Disorders of thrombosis (2012) (0)
Acquired Circulating Anticoagulants And Defective Hemostasis In Malignant Paraprotein Disorders (2019) (0)
MolecularMarkers of HemostaticDisorders:Implicationsin the Diagnosis and Therapeutic Managementof Thromboticand BleedingDisorders (1983) (0)
Clinical Case Reports (1974) (0)
RECOMBINANT THROMBOMODULIN DOES NOT CROSS REACT WITH ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES. POTENTIAL IMPLICATION FOR ANTICOAGULATION OF HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS (2007) (0)
Recombinant Thrombomodulin Does Not Cross React with Anti‐heparin Platelet Factor 4 Antibodies. Potential Implication in the Anticoagulant Management of Heparin Induced Thrombocytopenia Patients (2007) (0)
An Update on Antiphospholipid Syndrome (2006) (0)
COMPARISON OF ANTITHROMBIN III ASSAYS: METHODS OF CHOICE (1983) (0)
Prevalence of heparin induced thrombocytopenia antibodies in cancer patients treated with a low molecular weight heparin (2008) (0)
Letter: Prothrombin complex concentrates and chronic liver disease. (1975) (0)
Thorotrast-Induced Angiosarcoma Complicated by Disseminated Intravascular Coagulation and Microangiopathic Hemolytic Anemia: Case Report and Review (1995) (0)
Upregulation of Inflammatory Mediators in Lung Cancer and Their Modulation by Oral Anticoagulant Therapy (2007) (0)
A Systematic Approach To The Diagnosis Of Bleeding Disorders (2019) (0)
Bick State-ofthe-Art Review : Antiphospholipid Thrombosis Syndromes (2007) (0)
PLATELET DYSFUNCTION INDUCED BY TETRAHYDROCANNABINOL (1987) (0)
The clinical relevance of plasminogen activator assays. (1989) (0)
Hypercoagulability In Diabetes And Its Correction By An Antiplatlet Drug: Piracetam (1981) (0)
SEMINARS IN THROMBOSIS AND HEMOSTASIS Bibliothek Mund « n (2011) (0)
Pitfalls in Warfarin Therapy (2006) (0)
State-of-the-Art Review Hereditary and Acquired Thrombophilic Disorders (2006) (0)
Basic Concepts of Hemostasis and Thrombosis (2019) (0)
Factor V: a simplified one-stage using a stabilized artificial substrate. (1973) (0)
Syndromes Associated with Hyperfibrino(GENO)Lysis (2019) (0)
Hematological Complications in Obstetrics, Pregnancy, and Gynecology: Low molecular weight heparins in pregnancy (2006) (0)
Process for the recovery of antithrombin III (1977) (0)
Low Molecular Weight Heparins : Basic and Applied Considerations (2004) (0)
Compositional variations in porcine mucosal heparins used for the production of low molecular weight heparins. Impact on generic low molecular weight heparin development (2007) (0)
Primary Hyperfibrino(Geno)Lytic Syndromes (2019) (0)
Vascular Disorders (2019) (0)
Hereditary Plasma Protein Disorders (2019) (0)
Thrombolytic Therapy (2019) (0)
Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis. (2007) (0)
Alterations Of Hemostasis During Cardiopulmonary Bypass (CPB): A Comparison Between Membrane And Bubble Oxygenators (1981) (0)
Heparin-induced thrombocytopenia in pregnancy (2006) (0)
Fully automated antithrombin-III assays by synthetic substrate on the Multistat III. (1987) (0)
Letter: Prothrombin complex concentrates and chronic liver disease. (1975) (0)
Professor Hans Klaus Breddin (1928-2006): A World-Class Physician, Mentor, and Friend (2007) (0)
Disseminated intravascular coagulation syndromes. (1992) (0)
Prevalence of Anti‐human and Anti‐bovine Thrombin Antibodies in Healthy Individuals and Patients with End Stage Renal Disease (2007) (0)
Basic Mechanisms of Hemostasis Pertaining to DIC (2019) (0)
LETTER TO THE EDITORS-IN-CHIEF PROTHROMBIN COMPLEX CONCENTRATES AND CHRONIC LIVER DISEASE (1975) (0)
Needle malaria. (1971) (0)
OF NORTH AMERICA Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management (0)
Oral anticoagulants and the INR: confusion, controversy, fiction, and fact. (1994) (0)
Abstracts of current literature (1954) (0)
Comprar Hematological Complications in Obstetrics, Pregnancy, and Gynecology | Rodger L. Bick | 9780521108690 | Cambridge University Press (2009) (0)
Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants (2006) (0)
Hematological Complications in Obstetrics, Pregnancy, and Gynecology: Preface (2006) (0)
Clinical Use of Platelet Adhesion (1977) (0)
Dr. Bick’s Reply (1984) (0)
A Comparison Of Chr0M0Genic, Flu0R0Genic, And Fibrinogen Substrate Assays For The Determination Of Plasma Heparin (1981) (0)
Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications. (2006) (0)
Book Reviews : Sickle Cell Disease: Basic Principles in Clinical Prac tice. S. H. Embury, R. P. Hebbel, N. Mohandas, and M. H. Steinberg (eds.). Raven Press, New York, NY, 1994, 902 pp., $145 (1995) (0)
Book Reviews : Clinical Applications of Doppler Ultrasound. 2nd ed. Kenneth J. W. Taylor, Peter N. Burns, and Peter N. T. Wells (eds.). Raven Press, New York, 399 pp (1996) (0)
HEMODIALYSIS DOWN REGULATES THE INFLAMMATORY MEDIATORS IN PATIENTS WITH END STAGE RENAL DISEASE (2007) (0)
Disseminated Intravascular Coagulation and Related Syndromes (2019) (0)
Antiinflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors. Experimental and Clinical Observations (2007) (0)
Pocket atlas of hematology (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rodger L. Bıck?

Rodger L. Bıck is affiliated with the following schools:

Rodger L. Bıck's Academic­Influence.com Rankings

Rodger L. Bıck's Degrees

Why Is Rodger L. Bıck Influential?

Rodger L. Bıck's Published Works

Published Works

What Schools Are Affiliated With Rodger L. Bıck?

Rodger L. Bıck's AcademicInfluence.com Rankings